Placebo low dose

DRUG3 trials

Sponsors

University of Oxford, Charles Drew University of Medicine and Science, WinSanTor, Inc

Conditions

Diabetic Neuropathies, PainfulHIV-1Oxidative StressPainful Diabetic NeuropathyPeripheral Neuropathy

Phase 1

Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART

TerminatedNCT01024842

University of OxfordHIV-1

Start: 2009-12-31End: 2013-11-30Updated: 2016-06-08

The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels

CompletedNCT01251315

Charles Drew University of Medicine and ScienceOxidative Stress

Start: 2010-12-31End: 2011-06-30Updated: 2014-04-14

Phase 2

A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy

CompletedNCT04005287

WinSanTor, IncDiabetic Neuropathies, Painful, Painful Diabetic Neuropathy, Peripheral Neuropathy

Start: 2019-10-15End: 2021-12-15Updated: 2022-12-16

Related Papers

Topical application of the antimuscarinic pirenzepine increased lower limb nerve fibre density in a phase 2a study in type 2 patients with diabetes with peripheral neuropathy.

2025-12-05

Evaluation of the immunogenicity and impact on the latent HIV‐1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy‐treated subjects

Journal of the International AIDS Society2017-01-0132 citations